FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileMemphasys Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
MEM.AX
Memphasys Limited Stock AnalysisComprehensive stock analysis for Memphasys Limited (MEM.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisMEM.AX
MEM.AX
Memphasys Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
MEM.AX
  1. Home
  2. Stocks
  3. Memphasys Limited

Memphasys Limited

🇦🇺MEM.AX•ASX

Memphasys Limited

🇦🇺MEM.AX•ASX

Your view on MEM.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Memphasys Limited

Industry
Biotechnology
Sector
Healthcare
CEO
R. John Aitken
Headquarters
30 Richmond Road, Homebush, NSW, AU
Industry
Biotechnology
Sector
Healthcare
CEO
R. John Aitken
Headquarters
30 Richmond Road, Homebush, NSW, AU
Description

Memphasys Limited, an Australian enterprise, is dedicated to the development, manufacturing, and distribution of advanced cell and protein separation technologies, alongside associated consumable goods, for the healthcare, veterinary, and biotechnology sectors.

Its leading innovation is Felix, an automated device engineered to swiftly and gently isolate high-quality sperm from raw semen samples, primarily for use in human in vitro fertilization (IVF) procedures.

The company's product portfolio also includes ROSA, a rapid oxidative stress assay; the Samson Device, designed for quick equine pregnancy prediction; SemPort, a system for central laboratory human semen analysis from geographically dispersed donors; and AI-Port, an ambient temperature semen transport solution for animal artificial insemination.

Incorporated in 2006, the company was formerly known as NuSep Holdings Limited until its rebranding to Memphasys Limited in July 2016, and is headquartered in Homebush, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Memphasys Limited. Starting points for Memphasys Limited: beta 0.47 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Memphasys Limited. Memphasys Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Memphasys Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Memphasys Limited. Memphasys Limited has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold MEM.AX20 companies
Compare MEM.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ACR.AXAcrux LimitedHealthcareBiotechnology—
BGT.AXBio-Gene Technology LimitedBasic MaterialsAgricultural Inputs—
BIT.AXBiotron LimitedHealthcareBiotechnology—
CAN.AXCann Group LimitedHealthcareDrug Manufacturers - Specialty & Generic—
CHM.AXChimeric Therapeutics LimitedHealthcareBiotechnology—
HIQ.AXHITIQ LimitedHealthcareMedical - Healthcare Information Services—
IBX.AXImagion Biosystems LimitedHealthcareMedical - Diagnostics & Research—
IVX.AXInvion LimitedHealthcareDrug Manufacturers - Specialty & Generic—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PRRUFImmutep LimitedHealthcareOTC$368.0M
PRTAProthena Corporation plcHealthcareNASDAQ$428.8M
PRTCYPureTech Health plcHealthcareOTC—
PRVCFPreveCeutical Medical Inc.HealthcareOTC$10.1M
PSYBFPsyBio Therapeutics Corp.HealthcareOTC$1,275
PTCHFPureTech Health plcHealthcareOTC$410.4M
PTCTPTC Therapeutics, Inc.HealthcareNASDAQ$5.0B
PTGXProtagonist Therapeutics, Inc.HealthcareNASDAQ$8.3B
PTHSPelthos Therapeutics Inc.HealthcareAMEX$27.9M
PTIXProtagenic Therapeutics, Inc.HealthcareNASDAQ$470,654
PTNPalatin Technologies, Inc.HealthcareNASDAQ$9.2M
PTX.AXPrescient Therapeutics LimitedHealthcareASX—
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Memphasys Limited.

MEM.AX AnalysisFair
Past
2
Growth
5
Health
3
Profit
1
Value
1